Your Article Summary
See Latest ArticlesPhase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors
Clinical Cancer Research, 06/17/09
Tan AR et al. - In a trial to evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of eribulin mesylate (E7389) administered every 21 days in pts with advanced solid tumors, it was shown that eribulin mesylate has a manageable toxicity profile at 2 mg/m2, with further dose escalation limited by neutropenia.
Methods- Eribulin mesylate was given as a 1-hr infusion every 21 days at doses of 0.25, 0.5, 1, 2, 2.8, and 4 mg/m2.
- The MTD was identified using an accelerated titration design.
- The pharmacokinetics of eribulin were evaluated in the plasma and urine with the first dose.
- 21 pts were enrolled.
- At 4 mg/m2, 3 pts experienced a DLT of febrile neutropenia on day 7.
- Dose level was reduced to 2.8 mg/m2 where 2 of 3 pts experienced dose-limiting febrile neutropenia.
- 6 additional pts were enrolled at 2 mg/m2 (7 pts received this dose) and 1 of these pts experienced a neutropenic DLT.
- MTD of eribulin mesylate was 2 mg/m2.
- Nonhematologic toxicities included alopecia, fatigue, anorexia, and nausea.
- Pharmacokinetic analysis showed linear kinetics for eribulin over the dose range studied and a terminal half-life of 2 days.
- Plasma-concentration-time profile exhibited a rapid distribution phase followed by a slow elimination phase.
- Drug clearance was nonrenal.
- 1 pt with non–small cell lung cancer achieved an unconfirmed partial response and 12 pts had stable disease.
Related Articles
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09
Relevance Score: 80%
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 10/01/09
Relevance Score: 80%
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Clinical Cancer Research, 10/01/09
Relevance Score: 80%
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: Results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors
Journal of Clinical Oncology, 11/13/09
Relevance Score: 79%
A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Clinical Cancer Research, 10/15/09
Relevance Score: 79%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/17/09
Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4?,5-trimethoxylstilbene-3?-O-phosphate disodium (M410)
Investigational New Drugs, 12/17/09
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
Neuro-Oncology, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/16/09
A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL)
Cancer, 12/16/09